Telix Pharma Q2 Revenue Up 63%; Confirms FY25 Revenue Guidance
22/7 10:39
(RTTNews) - Telix Pharmaceuticals Limited (TLX) issued an update on its commercial and operational performance for the quarter ended 30 June 2025. Second quarter group revenue was approximately $204 million, up 63% year-over-year. Global Illuccix revenue was $154 million, an incr...